ArticleFrontiers in pharmacology2025
Therapeutic efficacy of deslanoside in oleic acid-induced acute lung injury in rabbits: Implications for clinical drug use and pharmacological strategies.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute lung injury (ALI) remains a life-threatening condition with limited effective pharmacological options. Deslanoside, a cardiac glycoside traditionally used in heart failure, has recently attracted attention for its anti-inflammatory and tissue-protective properties. Objective: This study evaluated the therapeutic efficacy of deslanoside in an oleic acid-induced rabbit ALI model and discussed its potential clinical and pharmacological implications. Deslanoside is known to modulate Na Methods: Thirty healthy male New Zealand white rabbits were randomly assigned to control (saline) or experimental (deslanoside) groups following intravenous oleic acid injection to induce ALI. Modified lung ultrasound (MLUS) scores, arterial blood gas analysis, lung water content, histopathology, and serum levels of TNF-α, IL-1β, and IL-6 were assessed over 12 h. Results: Compared with controls, deslanoside treatment significantly improved PaO Conclusion: Deslanoside demonstrated significant protective effects in oleic acid-induced ALI, improving oxygenation, attenuating pulmonary edema, and reducing inflammation. These findings support the potential repositioning of deslanoside as an adjunctive therapy for ALI and provide experimental evidence to inform future clinical drug use strategies and pharmacological policy discussions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.